REMUS
Start SIP
Invest Now
Start SIP in REMUS
Performance
- Low
- ₹690
- High
- ₹798
- 52 Week Low
- ₹611
- 52 Week High
- ₹1,289
- Open Price₹690
- Previous Close₹693
- Volume41,400
Investment Returns
- Over 1 Month + 7.77%
- Over 3 Month + 6.39%
- Over 6 Month -18.69%
- Over 1 Year -38.11%
Smart Investing Starts Here Start SIP with Remus Pharmaceuticals for Steady Growth!
Remus Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 31.2
- PEG Ratio
- -
- Market Cap Cr
- 906
- P/B Ratio
- 3
- Average True Range
- 36.18
- EPS
- 24.53
- Dividend Yield
- 0.1
- MACD Signal
- 1.92
- RSI
- 60.39
- MFI
- 71.25
Remus Pharmaceuticals Financials
Remus Pharmaceuticals Technicals
EMA & SMA
Current Price
₹768.90
+
75.55
(10.9%)
- Bearish Moving Average 3
- Bullish Moving Average 13
- 20 Day
- ₹719.32
- 50 Day
- ₹726.92
- 100 Day
- ₹768.84
- 200 Day
- ₹844.91
Resistance and Support
752.27
- R3 922.73
- R2 860.37
- R1 814.63
- S1 706.53
- S2 644.17
- S3 598.43
Remus Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-10 | Quarterly Results & Interim Dividend | |
| 2025-05-17 | Audited Results, Dividend & Others | To consider 1. Bonus 2. Other business matters. Interim Dividend of Rs. 2 per equity share. |
| 2024-11-09 | Quarterly Results & Interim Dividend | To consider other business matters. Interim Dividend of Rs. 2 per equity share. |
| 2024-05-16 | Audited Results | |
| 2024-04-23 | Bonus issue & Interim Dividend |
Remus Pharmaceuticals F&O
About Remus Pharmaceuticals
- NSE Symbol
- REMUS
- BSE Symbol
- Managing Director
- Mr. Arpit Deepakkumar Shah
- ISIN
- INE0O5T01011
Similar Stocks to Remus Pharmaceuticals
Remus Pharmaceuticals FAQs
Remus Pharmaceuticals share price is ₹768 As on 02 January, 2026 | 21:24
The Market Cap of Remus Pharmaceuticals is ₹906.1 Cr As on 02 January, 2026 | 21:24
The P/E ratio of Remus Pharmaceuticals is 31.2 As on 02 January, 2026 | 21:24
The PB ratio of Remus Pharmaceuticals is 3 As on 02 January, 2026 | 21:24
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.